Latest Organon News & Updates

See the latest news and media coverage for Organon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Organon

Global healthcare company focused on women's health

organon.com

Headquarters: Jersey City, United States
Company type: Public company
Number of employees: 10,000+

Last updated Today

Latest news about Organon

In short: Organon entered a definitive agreement to be acquired by Sun Pharma for $11.75 billion and received several FDA and EC approvals for its biosimilars.

Company announcements

June 10 Organon

Organon expands TOFIDENCE use to CRS and pediatric COVID-19

The FDA approved the biosimilar for treating CAR T-cell induced CRS and COVID-19 in patients aged 2 and older.

April 29 Organon

EC approves Organon and Henlius's POHERDY biosimilar

POHERDY is the first approved pertuzumab biosimilar in Europe for HER2-positive breast cancer treatments. It expands access via Organon's commercialization rights.

April 26 Organon

Organon sells to Sun Pharma

The sale is announced on April 26, 2026.

April 15 Organon

Organon’s VTAMA cream receives strong AAD recommendation

The 2026 guidelines endorse it as the only steroid-free topical for pediatric atopic dermatitis across severities in children aged 2+.

Media coverage

Yesterday TipRanks

Organon Sets July Vote on $14‑per‑Share Sun Pharma Takeover - TipRanks.com

New activity is brewing for Organon ( ($OGN) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This...

Yesterday GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

The investigation concerns whether the Organon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction...

June 11 Devdiscourse

Organon Wins Approval: Advancements in Health Amid Ebola Challenges

Organon receives U.S. FDA approval to expand the use of its biosimilar arthritis drug for certain cancer and COVID-19 patients. Concurrently, health systems face issues...

June 10 Citeline

Organon Adds Two New Indications For Its Actemra Biosimilar Rival

Organon closes an indication gap with Tofidence, but subcutaneous availability and market share remain areas where its tocilizumab biosimilar still lags behind.

Never miss news about Organon

Track Organon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.